European Society for Medical Oncology (ESMO)

American Society of Clinical Oncology (ASCO)

ESMO colorectal cancer guidelines

Schmoll HJ, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer: a personalised approach to clinical decision making. Ann Oncol 2012;23:2479-2516.
Web: Click here

Expert Group on OncoSurgery management of Liver Metastases (EGOSLIM) colorectal cancer guidelines on liver metastases

Adam R et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012;17(10):1225-1239.
Web: Click here

The PRIME study

Douillard J-Y et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-1034.
Web: Click here

The PEAK study

Schwartzberg L et al. PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014, March 31 (published online before print).
Web: Click here

Management of skin toxicity with anti- EGFR treatment

ESMO: Management of skin toxicities from EGFR inhibitor therapies (for healthcare professionals).
Web: Click here

European Medicines Agency

European Public Assessment Report (EPAR) for Vectibix^®
Web: Click here